We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
An FDA advisory committee voted on Thursday to recommend approval of Paratek’s new antibiotic, omadacycline, for the treatment of acute bacterial skin infections and community-acquired bacterial pneumonia (CABP).